List of Ninlaro drug patents

Ninlaro is owned by Takeda Pharms Usa.

Ninlaro contains Ixazomib Citrate.

Ninlaro has a total of 9 drug patents out of which 0 drug patents have expired.

Ninlaro was authorised for market use on 20 November, 2015.

Ninlaro is available in capsule;oral dosage forms.

Ninlaro can be used as use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

The generics of Ninlaro are possible to be released after 20 November, 2029.

NINLARO's oppositions filed in EPO
Can you believe NINLARO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546608 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(1 year, 2 months from now)

US8003819 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US8530694 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US7687662 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US8859504 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof
Jun, 2029

(6 years from now)

US7442830 TAKEDA PHARMS USA Proteasome inhibitors
Nov, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233115 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(1 year, 2 months from now)

US8871745 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US9175017 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof
Jun, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 20, 2022

Drugs and Companies using IXAZOMIB CITRATE ingredient

Market Authorisation Date: 20 November, 2015

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

How can I launch a generic of NINLARO before it's patent expiration?
More Information on Dosage

NINLARO family patents

47

United States

15

China

12

Korea, Republic of

12

Hong Kong

10

Japan

10

European Union

9

Israel

8

Taiwan

7

Argentina

7

New Zealand

6

Brazil

EA

6

EA

6

South Africa

6

Peru

5

Mexico

4

Canada

4

Philippines

4

Ukraine

4

Denmark

4

Malaysia

4

Spain

4

Portugal

3

Georgia

3

Poland

3

Slovenia

3

Costa Rica

3

Cyprus

3

Croatia

3

Australia

3

Norway

3

Ecuador

3

Singapore

2

Chile

2

RS

1

Dominican Republic

1

Luxembourg

1

Lithuania

1

Iceland

1

Germany

1

Morocco

1

Netherlands

1

Hungary

1

Colombia

1

Austria

1

Tunisia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic